188 related articles for article (PubMed ID: 35818069)
1. EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.
Chang P; Chen S; Chang X; Zhu J; Tang Q; Ma L
Eur J Med Res; 2022 Jul; 27(1):115. PubMed ID: 35818069
[TBL] [Abstract][Full Text] [Related]
2. Survival Prognosis, Tumor Immune Landscape, and Immune Responses of ADAMTS14 in Clear Cell Renal Cell Carcinoma and Its Potential Mechanisms.
Chen Y; Ji H; Liu S; Xing Q; Zhu B; Wang Y
Front Immunol; 2022; 13():790608. PubMed ID: 35572505
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value and immunological role of AXL gene in clear cell renal cell carcinoma associated with identifying LncRNA/RBP/AXL mRNA networks.
Wang Y; Tian Y; Liu S; Wang Z; Xing Q
Cancer Cell Int; 2021 Nov; 21(1):625. PubMed ID: 34838035
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
5. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract][Full Text] [Related]
6. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer.
Wei C; Liang Q; Li X; Li H; Liu Y; Huang X; Chen X; Guo Y; Li J
J Cell Biochem; 2019 Sep; 120(9):14916-14927. PubMed ID: 31016791
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of long noncoding RNA LINC00683 associated with unfavorable prognosis in prostate cancer based on TCGA.
Liu Y; Yang B; Su Y; Xiang Q; Li Q
J Cell Biochem; 2019 Aug; 120(8):14165-14174. PubMed ID: 30963639
[TBL] [Abstract][Full Text] [Related]
9. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract][Full Text] [Related]
10. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
11. Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms.
Wang Y; Liu S; Chen Y; Zhu B; Xing Q
World J Oncol; 2022 Feb; 13(1):27-37. PubMed ID: 35317332
[TBL] [Abstract][Full Text] [Related]
12. Identification of HCG18 and MCM3AP-AS1 That Associate With Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer.
Chen Y; Chen Z; Mo J; Pang M; Chen Z; Feng F; Xie P; Yang B
Technol Cancer Res Treat; 2021; 20():1533033821990064. PubMed ID: 33596783
[TBL] [Abstract][Full Text] [Related]
13. Five lncRNAs Associated With Prostate Cancer Prognosis Identified by Coexpression Network Analysis.
Gong X; Ning B
Technol Cancer Res Treat; 2020; 19():1533033820963578. PubMed ID: 33084528
[TBL] [Abstract][Full Text] [Related]
14. Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer.
Zhang P; Gao H; Ye C; Yan R; Yu L; Xia C; Yang D
Front Immunol; 2022; 13():905259. PubMed ID: 35720323
[TBL] [Abstract][Full Text] [Related]
15. Analyzing the LncRNA, miRNA, and mRNA Regulatory Network in Prostate Cancer with Bioinformatics Software.
He JH; Han ZP; Zou MX; Wang L; Lv YB; Zhou JB; Cao MR; Li YG
J Comput Biol; 2018 Feb; 25(2):146-157. PubMed ID: 28836827
[TBL] [Abstract][Full Text] [Related]
16. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
17. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
18. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
20. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]